Ionis Pharmaceuticals Drops Another After Phase 3 Setback
Ionis Pharmaceuticals dropped again after a Phase 3 failure in transthyretin amyloid cardiomyopathy, triggering a bro...
Compare ownership costs across dividend ETFs to identify which option offers the best balance of cost, yield, and risk.
22,825 articlesIonis Pharmaceuticals dropped again after a Phase 3 failure in transthyretin amyloid cardiomyopathy, triggering a bro...
A Brooklyn rehab clinic case has public officials chasing a suspected scam spanning years. This article breaks down w...
American creators are turning Erling Haaland into the breakout World Cup brand, driving merch sales and new sponsorsh...
JPMorgan Chase's CEO says the public frustration with wealth concentration is real, and calls for policy and corporat...
New December 2025 data underscores a sizable gap in benefits for claiming at 62 versus waiting to 70, changing how in...
A cardinal tetra’s journey from the Amazon to home tanks reveals how the global aquarium trade touches personal finan...
A tempting promise of free phones drew unsuspecting customers into a mailbox scam that police say ended with dozens o...
Investors are watching Meta’s next moves as chatter around a cloud-scale partnership heats up. This piece explains wh...
Intel stock has moved faster than its turnaround plan in many eyes. As Lip-Bu Tan reshapes the company, investors mus...
Prices are cooling and mortgage rates linger above historical lows. This piece unpacks whether we’re at a turning poi...
Friday brought a notable rally for Integer Holdings as earnings beat and optimistic analyst updates boosted sentiment...
When sentiment hits extreme fear, smart investors pause and plan. This guide explains what the crypto market flashing...